Li Shu, Yu Tao, Tian Yiwei, McCoy Colin P, Jones David S, Andrews Gavin P
Pharmaceutical Engineering Group, School of Pharmacy, Medical Biology Centre, Queen's University , Belfast BT9, Northern Ireland.
Mol Pharm. 2016 Sep 6;13(9):3054-68. doi: 10.1021/acs.molpharmaceut.6b00134. Epub 2016 Jul 26.
Engineered cocrystals offer an alternative solid drug form with tailored physicochemical properties. Interestingly, although cocrystals provide many new possibilities, they also present new challenges, particularly in regard to their design and large-scale manufacture. Current literature has primarily focused on the preparation and characterization of novel cocrystals typically containing only the drug and coformer, leaving the subsequent formulation less explored. In this paper we propose, for the first time, the use of hot melt extrusion for the mechanochemical synthesis of pharmaceutical cocrystals in the presence of a meltable binder. In this approach, we examine excipients that are amenable to hot melt extrusion, forming a suspension of cocrystal particulates embedded in a pharmaceutical matrix. Using ibuprofen and isonicotinamide as a model cocrystal reagent pair, formulations extruded with a small molecular matrix carrier (xylitol) were examined to be intimate mixtures wherein the newly formed cocrystal particulates were physically suspended in a matrix. With respect to formulations extruded using polymeric carriers (Soluplus and Eudragit EPO, respectively), however, there was no evidence within PXRD patterns of either crystalline ibuprofen or the cocrystal. Importantly, it was established in this study that an appropriate carrier for a cocrystal reagent pair during HME processing should satisfy certain criteria including limited interaction with parent reagents and cocrystal product, processing temperature sufficiently lower than the onset of cocrystal Tm, low melt viscosity, and rapid solidification upon cooling.
工程共晶提供了一种具有定制物理化学性质的替代固体药物形式。有趣的是,尽管共晶提供了许多新的可能性,但它们也带来了新的挑战,特别是在其设计和大规模制造方面。目前的文献主要集中在通常仅包含药物和共形成剂的新型共晶的制备和表征上,而后续的制剂研究较少。在本文中,我们首次提出在可熔性粘合剂存在下,使用热熔挤出法进行药物共晶的机械化学合成。在这种方法中,我们研究了适合热熔挤出的辅料,形成了嵌入药物基质中的共晶颗粒悬浮液。以布洛芬和异烟酰胺作为共晶试剂对的模型,研究了用小分子基质载体(木糖醇)挤出的制剂,发现它们是紧密混合物,其中新形成的共晶颗粒物理悬浮在基质中。然而,对于分别使用聚合物载体(Soluplus和Eudragit EPO)挤出的制剂,在粉末X射线衍射图谱中没有结晶布洛芬或共晶的证据。重要的是,本研究确定,在热熔挤出过程中,共晶试剂对的合适载体应满足某些标准,包括与母体试剂和共晶产物的相互作用有限、加工温度远低于共晶熔点的起始温度、低熔体粘度以及冷却后快速固化。